Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b

Steven R. Schwid, Andrew D. Goodman, David Mattson

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Objective: To report symptomatic autoimmune hyperthyroidism developing in patients with multiple sclerosis (MS) treated with interferon beta-1b (IFN-β-1b). Report of Cases: A 44-year-old woman experienced gradually worsening fatigue, depression, and motor function several months after beginning therapy with IFN-β-1b for MS. Graves disease associated with episodic palpitations, shortness of breath, hair loss, increased appetite, weight loss, and insomnia was confirmed with endocrinologic studies. Increased fatigue and weakness developed in a 52-year-old woman several months after starting IFN-β-1b therapy. She also noted sweats, heat intolerance, palpitations, increased appetite, and irritability, and endocrinologic evaluation supported a diagnosis of Graves disease. Conclusions: To our knowledge, this is the first report of autoimmune thyroid disease associated with IFNβ-1b treatment in patients with MS. Psoriasis has also been reported during interferon therapy for MS, and similar phenomena occur during interferon therapy for hepatitis C. Since some symptoms of thyroid dysfunction may be difficult to distinguish from typical MS-related symptoms, thyroid hormone levels should be checked when unexplained constitutional symptoms occur during IFNβ-1b therapy.

Original languageEnglish (US)
Pages (from-to)1169-1170
Number of pages2
JournalArchives of Neurology
Volume54
Issue number9
StatePublished - Sep 1997
Externally publishedYes

Fingerprint

Graves Disease
Multiple Sclerosis
Appetite
Interferons
Fatigue
Therapeutics
Sweat
Alopecia
Thyroid Diseases
Sleep Initiation and Maintenance Disorders
Hepatitis C
Thyroid Hormones
Psoriasis
Dyspnea
Autoimmune Diseases
Interferon beta-1b
Therapy
Weight Loss
Thyroid Gland
Hot Temperature

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. / Schwid, Steven R.; Goodman, Andrew D.; Mattson, David.

In: Archives of Neurology, Vol. 54, No. 9, 09.1997, p. 1169-1170.

Research output: Contribution to journalArticle

@article{2b000fc029cf4ef1bdc7c63853005af3,
title = "Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b",
abstract = "Objective: To report symptomatic autoimmune hyperthyroidism developing in patients with multiple sclerosis (MS) treated with interferon beta-1b (IFN-β-1b). Report of Cases: A 44-year-old woman experienced gradually worsening fatigue, depression, and motor function several months after beginning therapy with IFN-β-1b for MS. Graves disease associated with episodic palpitations, shortness of breath, hair loss, increased appetite, weight loss, and insomnia was confirmed with endocrinologic studies. Increased fatigue and weakness developed in a 52-year-old woman several months after starting IFN-β-1b therapy. She also noted sweats, heat intolerance, palpitations, increased appetite, and irritability, and endocrinologic evaluation supported a diagnosis of Graves disease. Conclusions: To our knowledge, this is the first report of autoimmune thyroid disease associated with IFNβ-1b treatment in patients with MS. Psoriasis has also been reported during interferon therapy for MS, and similar phenomena occur during interferon therapy for hepatitis C. Since some symptoms of thyroid dysfunction may be difficult to distinguish from typical MS-related symptoms, thyroid hormone levels should be checked when unexplained constitutional symptoms occur during IFNβ-1b therapy.",
author = "Schwid, {Steven R.} and Goodman, {Andrew D.} and David Mattson",
year = "1997",
month = "9",
language = "English (US)",
volume = "54",
pages = "1169--1170",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b

AU - Schwid, Steven R.

AU - Goodman, Andrew D.

AU - Mattson, David

PY - 1997/9

Y1 - 1997/9

N2 - Objective: To report symptomatic autoimmune hyperthyroidism developing in patients with multiple sclerosis (MS) treated with interferon beta-1b (IFN-β-1b). Report of Cases: A 44-year-old woman experienced gradually worsening fatigue, depression, and motor function several months after beginning therapy with IFN-β-1b for MS. Graves disease associated with episodic palpitations, shortness of breath, hair loss, increased appetite, weight loss, and insomnia was confirmed with endocrinologic studies. Increased fatigue and weakness developed in a 52-year-old woman several months after starting IFN-β-1b therapy. She also noted sweats, heat intolerance, palpitations, increased appetite, and irritability, and endocrinologic evaluation supported a diagnosis of Graves disease. Conclusions: To our knowledge, this is the first report of autoimmune thyroid disease associated with IFNβ-1b treatment in patients with MS. Psoriasis has also been reported during interferon therapy for MS, and similar phenomena occur during interferon therapy for hepatitis C. Since some symptoms of thyroid dysfunction may be difficult to distinguish from typical MS-related symptoms, thyroid hormone levels should be checked when unexplained constitutional symptoms occur during IFNβ-1b therapy.

AB - Objective: To report symptomatic autoimmune hyperthyroidism developing in patients with multiple sclerosis (MS) treated with interferon beta-1b (IFN-β-1b). Report of Cases: A 44-year-old woman experienced gradually worsening fatigue, depression, and motor function several months after beginning therapy with IFN-β-1b for MS. Graves disease associated with episodic palpitations, shortness of breath, hair loss, increased appetite, weight loss, and insomnia was confirmed with endocrinologic studies. Increased fatigue and weakness developed in a 52-year-old woman several months after starting IFN-β-1b therapy. She also noted sweats, heat intolerance, palpitations, increased appetite, and irritability, and endocrinologic evaluation supported a diagnosis of Graves disease. Conclusions: To our knowledge, this is the first report of autoimmune thyroid disease associated with IFNβ-1b treatment in patients with MS. Psoriasis has also been reported during interferon therapy for MS, and similar phenomena occur during interferon therapy for hepatitis C. Since some symptoms of thyroid dysfunction may be difficult to distinguish from typical MS-related symptoms, thyroid hormone levels should be checked when unexplained constitutional symptoms occur during IFNβ-1b therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030876399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030876399&partnerID=8YFLogxK

M3 - Article

C2 - 9311363

AN - SCOPUS:0030876399

VL - 54

SP - 1169

EP - 1170

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 9

ER -